5HVG

Crystal Structure of Thrombin-activatable Fibrinolysis Inhibitor in Complex with an Inhibitory Nanobody (VHH-a204)

Summary for 5HVG

• Entry DOI: 10.2210/pdb5hvg/pdb
• Related: 5HVF 5HVH
• Descriptor: Carboxypeptidase B2, VHH-a204, alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (7 entities in total)
• Functional Keywords: procarboxypeptidase u, thrombin-activatable fibrinolysis inhibitor, tafi, procarboxypeptidase r, plasma procarboxypeptidase b, nanobody, antibody fragment, protein complex, hydrolase/hydrolase inhibitor, hydrolase-hydrolase inhibitor complex
• Biological source: Homo sapiens (Human); More
• Total number of polymer chains: 4
• Total formula weight: 122698.04

Authors

Zhou, X.,Weeks, S.D.,Strelkov, S.V.,Declerck, P.J. (deposition date: 2016-01-28, release date: 2016-06-22, Last modification date: 2024-10-23)

Primary citation

Zhou, X.,Weeks, S.D.,Ameloot, P.,Callewaert, N.,Strelkov, S.V.,Declerck, P.J.
Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity.
J.Thromb.Haemost., 14:1629-1638, 2016

PubMed Abstract: Essentials Thrombin-activatable fibrinolysis inhibitor (TAFI) is a risk factor for cardiovascular disorders. TAFI inhibitory nanobodies represent a promising step in developing profibrinolytic therapeutics. We have solved three crystal structures of TAFI in complex with inhibitory nanobodies. Nanobodies inhibit TAFI through distinct mechanisms and represent novel profibrinolytic leads.

PubMed: 27279497
DOI: 10.1111/jth.13381

Experimental method

X-RAY DIFFRACTION (3.05 Å)